A serious adverse event secondary to rapid intravenous levetiracetam injection in a dog.

OBJECTIVE To describe a serious adverse event as a result of rapid intravenous injection of undiluted levetiracetam in a dog. CASE SUMMARY An 8-year-old female spayed Chihuahua was evaluated for cluster seizures and tachypnea. The patient was administered an intravenous dose of undiluted levetiracetam (60 mg/kg) and immediately developed tachycardia, hyperglycemia, hypotension, and a dull mentation. The patient's blood pressure and mentation did not respond to intravenous fluid boluses but improved immediately after administration of epinephrine intravenously. The patient subsequently developed respiratory failure necessitating mechanical ventilation, prior to cardiac arrest. Necropsy examination noted a pulmonary inflammatory cell infiltrate, pulmonary edema, and interstitial pneumonia. NEW OR UNIQUE INFORMATION PROVIDED This report documents a serious adverse event associated with intravenous levetiracetam administration to a dog.

[1]  D. Maria,et al.  Characterization of mesenchymal stem cells derived from the equine synovial fluid and membrane , 2015, BMC Veterinary Research.

[2]  G. Zaccara,et al.  The adverse event profile of levetiracetam: A meta-analysis on children and adults , 2015, Seizure.

[3]  C. Gurses,et al.  Intravenous levetiracetam treatment in status epilepticus: A prospective study , 2015, Epilepsy Research.

[4]  Qian Chen,et al.  Pharmacokinetics, Safety and Bioequivalence of Levetiracetam Intravenous Infusion and Oral Tablets in Healthy Chinese Subjects , 2015, Clinical Drug Investigation.

[5]  H. Volk,et al.  Assessment into the usage of levetiracetam in a canine epilepsy clinic , 2015, BMC Veterinary Research.

[6]  E. Patterson Status epilepticus and cluster seizures. , 2014, The Veterinary clinics of North America. Small animal practice.

[7]  D. Pearce,et al.  The Human Synaptic Vesicle Protein, SV2A, Functions as a Galactose Transporter in Saccharomyces cerevisiae * ♦ , 2014, The Journal of Biological Chemistry.

[8]  M. Wiese,et al.  Immediate‐type hypersensitivity drug reactions , 2014, British journal of clinical pharmacology.

[9]  E. Koklu,et al.  Levetiracetam-induced anaphylaxis in a neonate. , 2014, Pediatric neurology.

[10]  Y. Cortes,et al.  Anaphylaxis in dogs and cats. , 2013, Journal of veterinary emergency and critical care.

[11]  Xiao-feng Li,et al.  Stevens–Johnson syndrome induced by levetiracetam , 2012, Seizure.

[12]  R. McLachlan,et al.  Levetiracetam induced angioedema in a patient with previous anticonvulsant hypersensitivity reaction to phenytoin and lamotrigine , 2012, Seizure.

[13]  E. Patterson,et al.  Double-masked, placebo-controlled study of intravenous levetiracetam for the treatment of status epilepticus and acute repetitive seizures in dogs. , 2012, Journal of veterinary internal medicine.

[14]  Batool F. Kirmani,et al.  Use of intravenous levetiracetam for management of acute seizures in neonates. , 2011, Pediatric neurology.

[15]  A. Fischer,et al.  Status epilepticus and epileptic seizures in dogs. , 2009, Journal of veterinary internal medicine.

[16]  J. Wheless,et al.  Rapid Infusion of a Loading Dose of Intravenous Levetiracetam With Minimal Dilution: A Safety Study , 2009, Journal of child neurology.

[17]  Holger A Volk,et al.  The efficacy and tolerability of levetiracetam in pharmacoresistant epileptic dogs. , 2008, Veterinary journal.

[18]  E. Patterson,et al.  Intramuscular, intravenous and oral levetiracetam in dogs: safety and pharmacokinetics. , 2008, Journal of veterinary pharmacology and therapeutics.

[19]  Curtis Wells Dewey,et al.  Pharmacokinetics of single‐dose intravenous levetiracetam administration in normal dogs , 2008 .

[20]  Curtis Wells Dewey,et al.  Levetiracetam as an adjunct to phenobarbital treatment in cats with suspected idiopathic epilepsy. , 2008, Journal of the American Veterinary Medical Association.

[21]  S. Ramael,et al.  Levetiracetam Intravenous Infusion: A Randomized, Placebo‐controlled Safety and Pharmacokinetic Study , 2006, Epilepsia.

[22]  M. Morrell,et al.  The KEEPER™ 1 KEEPER is a trademark of UCB S.A. 1 trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community-based study , 2003, Epilepsy Research.

[23]  S. Platt,et al.  Canine status epilepticus: a retrospective study of 50 cases. , 2002, The Journal of small animal practice.

[24]  C. Hovinga Levetiracetam: A Novel Antiepileptic Drug , 2001, Pharmacotherapy.